Galantamine-induced improvements in cognitive function are not related to alterations in [alpha]4[beta]2 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET

• Published in: Psychopharmacology Vol. 202; no. 1-3; p. 79
• Main Authors: Ellis, J R, Nathan, P J, Villemagne, V L, Mulligan, R S, Saunder, T, Young, K, Smith, C L, Welch, J, Woodward, M, Wesnes, K A, Savage, G, Rowe, C C
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Nature B.V 01.01.2009
• Subjects: Alzheimer's disease; Cognition & reasoning; Pharmacology; Psychotropic drugs

The nicotinic acetylcholine receptor (nAChR) system plays a regulatory role in a number of cognitive processes. Cholinesterase inhibitors (i.e., galantamine) that potentiate cholinergic neurotransmission improve cognitive function in Alzheimer's disease (AD); however, the relationship between t...